Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | March 2012 |
| End Date: | October 2013 |
An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients
who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias
(PD-LID).
who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias
(PD-LID).
Inclusion Criteria:
- Patients who have completed a previous AFQ056A study or are eligible as defined in
the core study protocol
- Outpatients
- Patients who have a primary caregiver willing and able to assess the condition of the
patient throughout the study in accordance with protocol requirements
Exclusion Criteria:
- Atypical or secondary form of Parkinson's disease
- History of surgical treatment for PD including deep brain stimulation
- Advanced, severe, or unstable disease (other than PD)
- History of malignancy
- Evidence of dementia
- Untreated/ineffectively treated mental disorders
- Treatment with certain prohibited medications
- Abnormal lab values or heart abnormalities
- Pregnant or nursing women
We found this trial at
4
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials